Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
APRE•Program update and enrollment expansion
July 30 (Reuters) - Aprea Therapeutics Inc. APRE.O:
- Aprea Therapeutics provides Acesot-1051 program update for Wee1 inhibitor APR-1051, accelerating and expanding enrollment. Clinical data presentation planned for Q4 2026.
- Aprea Therapeutics said Acesot-1051 enrollment is accelerating to 6-10 patients per month by Q4 2026.
- The company expects to enroll at least 50 patients with USC or cyclin E-overexpressing PROC.
- Aprea Therapeutics said it is advancing APR-1051 in USC, PROC, and combination regimens in head and neck, colorectal cancer.
- Acesot-1051 clinical sites expand from three to ten.
- Dose escalation and backfill expansion are expected to complete in Q2 2027.
Source text: ID:nGNX5SqbLS
